Harpoon Therapeutics, Inc. HARP
At closeMar 8, 2024, 4:00 PM EST
52-week range unavailable
- Market cap
- 492.35M
- Revenue (ttm)
- 37.34M
- Profit margin
- -81.67%
- Shares out
- 21.40M
- Forward P/E
- -5.09
- Volume
- 6.40M
- Open
- 23.00
- Previous close
- 23.01
- Day's range
- 22.99 – 23.02
- Beta
- 2.10
- Analysts
- Buy
- Price target
- 24.79 (+7.7%)
- Earnings date
- Mar 25, 2024
1Y +16.31 (+243.43%)
Key statistics
- Enterprise value
- 381.33M
- PEG ratio
- 0.00
- Price / sales
- 13.19
- Price / book
- 20.82
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -67.30%
- Free cash flow
- -55.31M
- Total cash
- 31.61M
- Total debt
- 23.33M
- Return on equity
- -284.32%
- Short % of float
- 3.24%
- 50-day average
- 21.62
- 200-day average
- 11.15
Analyst view
Consensus: buy
- Target (low)
- 23.00
- Target (mean)
- 24.79
- Target (high)
- 27.00
- Strong buy2
- Buy0
- Hold7
- Sell0
- Strong sell0
Next earnings
Mar 25, 2024
Expected Mar 25, 2024. Consensus EPS estimate -0.50.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 25, 2024 | Dec 1, 2023 | -0.52 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -3.09 | — | — | — |
| Aug 9, 2023 | Jun 1, 2023 | -4.30 | — | — | — |
| May 11, 2023 | Mar 1, 2023 | -4.20 | — | — | — |
| Mar 27, 2023 | Dec 1, 2022 | -4.30 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -6.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 17, 2023 | Citigroup | main | Buy | Buy |
| Sep 13, 2023 | Canaccord Genuity | main | Buy | Buy |
| Sep 13, 2023 | HC Wainwright & Co. | main | Buy | Buy |
About Harpoon Therapeutics, Inc.
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- harpoontx.com
News
Merck Completes Acquisition of Harpoon Therapeutics, Inc. 
HARPOON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Harpoon Therapeutics, Inc. - HARP 
Merck Buys Harpoon Therapeutics To Expand Its Oncology Portfolio 
Shareholder Alert: Ademi LLP investigates whether Harpoon Therapeutics, Inc. has obtained a Fair Price in its transaction with Merck 
HARP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Harpoon Therapeutics, Inc. Is Fair to Shareholders 
Why LumiraDx Shares Are Trading Lower By Over 30%; Here Are 20 Stocks Moving Premarket 
Why Is Harpoon Therapeutics (HARP) Stock Up 111% Today? 
Merck to Buy Harpoon Therapeutics for $680 Million - Merck to buy Harpoon Therapeutics for $680 million
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline
Your note
Sign in to keep a note on HARP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAILES JOSEPH S | Director | Stock Award(Grant) | Nov 26, 2023 | 5,000 |
| CHIN MARK | Director | Stock Award(Grant) | Dec 28, 2023 | 12,801 |
| DRACHMAN JONATHAN G | Director | Stock Award(Grant) | Nov 26, 2023 | 5,000 |
| EASTLAND JULIA MARIE | Chief Executive Officer | Stock Award(Grant) | Jan 4, 2024 | 232,003 |
| HUNT RONALD M | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Dec 28, 2023 | 1,871,970 |
| LANZA FRANK J | Officer | Stock Award(Grant) | Jan 4, 2024 | 18,362 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BioImpact Capital LLC | 0.82% | 319,671 | 2.27M | Jun 29, 2023 |
| MPM Asset Management, LLC | 0.81% | 313,139 | 2.22M | Jun 29, 2023 |
| New Leaf Venture Partners, L.L.C. | 0.81% | 315,670 | 2.24M | Jun 29, 2023 |
| Franklin Resources, Inc. | 0.34% | 132,329 | 939.53K | Jun 29, 2023 |
| Vanguard Group Inc | 0.30% | 115,314 | 818.73K | Jun 29, 2023 |
| Artal Group S.A. | 0.26% | 100,000 | 710.00K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.18% | 69,106 | 490.65K | Jun 29, 2023 |
| Franklin Strategic Series-Franklin Biotechnology Discove | 0.11% | 44,530 | 348.80K | Jul 30, 2023 |
| Vanguard Extended Market Index Fund | 0.08% | 30,894 | 219.35K | Jun 29, 2023 |
| Tekla Life Sciences Investors | 0.07% | 25,991 | 184.54K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.03% | 12,252 | 83.31K | May 30, 2023 |
| Vanguard Variable Insurance Fund-Small Company Growth | 0.03% | 9,826 | 69.76K | Jun 29, 2023 |